Literature DB >> 20811700

Midkine expression is correlated with an adverse prognosis and is down-regulated by p53 in oral squamous cell carcinoma.

Kazutoshi Ota1, Hiromi Fujimori, Mitsuharu Ueda, Hirofumi Jono, Satoru Shinriki, Tomoko Ota, Takanao Sueyoshi, Manabu Taura, Ayaka Taguma, Hirofumi Kai, Masanori Shinohara, Yukio Ando.   

Abstract

Midkine (MK) expression has been documented to be inversely correlated with the prognosis of patients with various tumors, but the mechanism of this relationship has not been well characterized. Recent studies have also correlated p53 expression with prognosis of patients with oral squamous cell carcinoma (OSCC). We evaluated the relationship between MK expression and clinicopathological features of patients with OSCC to clarify the influence of p53 status on MK expression in OSCC cells. Our results showed that patients with MK over-expression in OSCC cells had a significantly lower 5-year survival rate compared with patients with low MK expression. Immunohistochemical analyses demonstrated overexpression of MK protein in OSCC samples with mutant p53. Cell culture experiments with human lingual squamous cell carcinoma revealed that the MK gene was regulated by the wild-type p53 gene. Thus, MK expression may affect prognosis via the p53 status and mutation of the p53 gene, and MK may be an attractive target for therapeutic intervention in patients with cancer cells with mutant p53.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811700     DOI: 10.3892/ijo_00000729

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  The clinical and prognostic significance of midkine in breast cancer patients.

Authors:  Fuguang Li; Peijun Tian; Jun Zhang; Changyuan Kou
Journal:  Tumour Biol       Date:  2015-07-10

Review 2.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

3.  Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.

Authors:  Hua Shao; Xiaohui Yu; Cuifang Wang; Qiang Wang; Haixia Guan
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 4.  Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells.

Authors:  Francesco Acquati; Laura Monti; Marta Lualdi; Marco Fabbri; Maria Grazia Sacco; Laura Gribaldo; Roberto Taramelli
Journal:  Oncotarget       Date:  2011-06

5.  Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins.

Authors:  Piroska Virag; Eva Fischer-Fodor; Maria Perde-Schrepler; Ioana Brie; Corina Tatomir; Loredana Balacescu; Ioana Berindan-Neagoe; Bogdan Victor; Ovidiu Balacescu
Journal:  BMC Genomics       Date:  2013-07-16       Impact factor: 3.969

6.  Midkine and NANOG Have Similar Immunohistochemical Expression Patterns and Contribute Equally to an Adverse Prognosis of Oral Squamous Cell Carcinoma.

Authors:  Hyun-Min Kim; Young-Hoon Kang; June-Ho Byun; Si-Jung Jang; Gyu-Jin Rho; Jong-Sil Lee; Bong-Wook Park
Journal:  Int J Mol Sci       Date:  2017-11-06       Impact factor: 5.923

7.  Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma.

Authors:  Ming-Chun Ma; Yi-Ju Chen; Tai-Jan Chiu; Jui Lan; Chien-Ting Liu; Yi-Ching Chen; Hsin-Ho Tien; Yen-Yang Chen
Journal:  BMC Cancer       Date:  2018-02-27       Impact factor: 4.430

8.  Prognostic value of Midkine expression in patients with solid tumors: a systematic review and meta-analysis.

Authors:  Luo Zhang; Xing Song; Yingjie Shao; Changping Wu; Jingting Jiang
Journal:  Oncotarget       Date:  2018-01-04

9.  Novel cytological model for the identification of early oral cancer diagnostic markers: The carcinoma sequence model.

Authors:  Masami Kawaharada; Manabu Yamazaki; Satoshi Maruyama; Tatsuya AbÉ; Nyein Nyein Chan; Taiichi Kitano; Tadaharu Kobayashi; Takeyasu Maeda; Jun-Ichi Tanuma
Journal:  Oncol Lett       Date:  2022-01-11       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.